Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Cash & Current Investments (2016 - 2025)

Cytokinetics (CYTK) has disclosed Cash & Current Investments for 16 consecutive years, with $882.2 million as the latest value for Q4 2025.

  • Quarterly Cash & Current Investments changed N/A to $882.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $882.2 million through Dec 2025, changed N/A year-over-year, with the annual reading at $882.2 million for FY2025, N/A changed from the prior year.
  • Cash & Current Investments for Q4 2025 was $882.2 million at Cytokinetics, down from $962.5 million in the prior quarter.
  • The five-year high for Cash & Current Investments was $1.1 billion in Q2 2024, with the low at $350.3 million in Q2 2021.
  • Average Cash & Current Investments over 5 years is $699.4 million, with a median of $619.3 million recorded in 2024.
  • The sharpest move saw Cash & Current Investments soared 92.83% in 2021, then tumbled 37.81% in 2023.
  • Over 5 years, Cash & Current Investments stood at $471.6 million in 2021, then soared by 66.27% to $784.2 million in 2022, then decreased by 21.55% to $615.2 million in 2023, then skyrocketed by 64.51% to $1.0 billion in 2024, then decreased by 12.83% to $882.2 million in 2025.
  • According to Business Quant data, Cash & Current Investments over the past three periods came in at $882.2 million, $962.5 million, and $858.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.